Patient Characteristics, Treatment Patterns, and Outcomes for Patients with Renal Cell Carcinoma in England: a Retrospective Cohort Study

Treatment pathways and survival outcomes were assessed for patients with the most common form of kidney cancer (renal cell carcinoma) in England using national data. In total, 32,577 patients were included. Over three quarters of patients were alive one year after diagnosis (93.2% in the non-metastatic subgroup and 37.1% among patients with metastases at diagnosis). Background and Objective: Considering the rapidly evolving treatment landscape of renal cell carcinoma (RCC), recent descriptions of the RCC population in the UK are lacking, as are real-world data on treatment and patient outcomes. To analyse the demographic and clinical characteristics, treatment patterns, and overall survival of patients with RCC using national data sets in England. Patients and Methods: This was a retrospective cohort study of patients diagnosed with RCC (all stages) between 2014-2018 using demographic, clinical, cancer registration, and treatment data. Patients were followed until death or study end (December 31, 2020). Treatments administered in each line were described to understand treatment sequencing. Kaplan-Meier methods were used for time-to-event analyses. Factors associated with discontinuation and survival were identified using Cox proportional hazard models. Results and Limitations: Among 32,577 included patients, the median age at diagnosis was 66 years, 63.4% were male, and 6,786 (20.8%) had metastatic RCC at diagnosis. Tyrosine kinase inhibitor (TKI) monotherapy was the most common treatment class across lines. Over three quarters of patients (78.5% [95% CI: 78.0-78.9]) were alive one year after diagnosis (93.2% in the non-metastatic at diagnosis subgroup and 37.1% among patients with metastases at diagnosis). At three years post initial diagnosis, 18.0% patients were alive in the metastatic at diagnosis subgroup. Rapid evolution of the treatment landscape limits the results regarding lines of therapy. Conclusion: This large-scale study provides insight on characteristics of patients with RCC, and it highlights the need for better treatment options to improve survival.